Any current/future new fundraising through debt or equity?

No specific information or announcements were made regarding current or future fundraising through debt or equity in the transcript. The company is in a strong financial position with zero long-term debt and a very low debt-equity ratio of 0.02. Cash flow from operations is strong at 225 million, supporting operational needs. Any future developments, including potential fundraising activities, are under secrecy agreements or not disclosed. Management prefers to share information proactively when appropriate and feasible, especially in physical meetings like AGMs. No explicit plans for debt or

Any current/future capex/capital investment/strategic investment?

Ongoing and upcoming projects include R&D on ceramic binders, acrylic dispersants (polycarboxylates and polyacrylamide solids). Feasibility study underway for a specialty chemical project in collaboration with a Japanese company. Discussions ongoing for two potential toll manufacturing projects with US and European companies; details under secrecy agreements. Manufacturing business CapEx remains largely unchanged at approximately ₹58 crores. Expansion potential exists: current acrylamide liquid capacity is 32,000 tons, with room to expand by another 60,000 tons. PAM Solid project is under R&D

Future growth expectations in sales/revenue/volumes?

The company anticipates revenue growth of 10-30% in the current year but will provide updates on a quarter-to-quarter basis as visibility improves. Q4 FY23 saw improving margins and the company expects this trend to continue with better results and opportunities ahead. Export volumes are being focused on due to higher realizations compared to the domestic market. Manufacturing revenues are expected to pick up in coming quarters, moving towards parity with distribution revenues. A fourfold increase in sales of N-methylol acrylamide is expected next quarter following customer approvals.

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects revenue growth of 10-30% in the year but will provide updates quarter-to-quarter rather than giving full-year guidance due to high uncertainty. EBITDA margins are currently in double digits and are expected to improve further with better procurement and inventory management. Margin improvements have already begun, especially on acrylamide products, with doubling of margins seen in the last quarter. The company is cautiously maintaining low inventory levels to benefit from raw material price falls and better margin stability. Earnings growth outlook is positive but i

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention details about the current or expected order book or pending orders. There is no direct disclosure regarding the size, value, or status of order books. Discussions focus more on financial performance, R&D projects (like PAM Solid), capacity, and market outlook. Confidentiality and secrecy agreements restrict sharing certain operational details, such as toll manufacturing plant specifics. Management emphasizes cautious optimism with improving margins and stabilization in markets but refrains from giving specific future orders or order book guidance. Fut

Black Rose Industries LtdQ4 FY23Chemicals & Petrochemicals

Black Rose Industries Ltd Q4 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹96.3P/E: 17.2Market Cap: ₹493 CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 3

The company anticipates revenue growth of 10-30% in the current year but will provide updates on a quarter-to-quarter basis as visibility improves.
Q4 FY23 saw improving margins and the company expects this trend to continue with better results and opportunities ahead.
Export volumes are being focused on due to higher realizations compared to the domestic market.
Manufacturing revenues are expected to pick up in coming quarters, moving towards parity with distribution revenues.
A fourfold increase in sales of N-methylol acrylamide is expected next quarter following customer approvals.
Ongoing R&D and feasibility studies with Japanese, US, and European partners may add future revenue streams.
Volume-wise, FY23 volumes for acrylamide were slightly lower than FY22, but Q4 volumes increased significantly.
Overall, the mood within the organization is positive with expectations of stabilization, market improvements, and profitability growth.

Margin guidance

Category 1

The company expects revenue growth of 10-30% in the year but will provide updates quarter-to-quarter rather than giving full-year guidance due to high uncertainty.
EBITDA margins are currently in double digits and are expected to improve further with better procurement and inventory management.
Margin improvements have already begun, especially on acrylamide products, with doubling of margins seen in the last quarter.
The company is cautiously maintaining low inventory levels to benefit from raw material price falls and better margin stability.
Earnings growth outlook is positive but incremental and gradual, with better profitability expected as market conditions stabilize and costs reduce.
EPS for FY23 was 1.29, and with improved margins and volumes, future EPS is expected to improve correspondingly.
Management prefers to update on earnings outlook quarter-wise to avoid misleading information due to market volatility.

See what Black Rose Industries Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

No specific information or announcements were made regarding current or future fundraising through debt or equity in the transcript.
The company is in a strong financial position with zero long-term debt and a very low debt-equity ratio of 0.02.
Cash flow from operations is strong at 225 million, supporting operational needs.
Any future developments, including potential fundraising activities, are under secrecy agreements or not disclosed.
Management prefers to share information proactively when appropriate and feasible, especially in physical meetings like AGMs.
No explicit plans for debt or equity fundraising were indicated during this webinar.

Order book

The transcript does not explicitly mention details about the current or expected order book or pending orders.
There is no direct disclosure regarding the size, value, or status of order books.
Discussions focus more on financial performance, R&D projects (like PAM Solid), capacity, and market outlook.
Confidentiality and secrecy agreements restrict sharing certain operational details, such as toll manufacturing plant specifics.
Management emphasizes cautious optimism with improving margins and stabilization in markets but refrains from giving specific future orders or order book guidance.
Future developments and significant updates will be shared in subsequent webinars or physical meetings when available.

See what Black Rose Industries Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Ongoing and upcoming projects include R&D on ceramic binders, acrylic dispersants (polycarboxylates and polyacrylamide solids).
Feasibility study underway for a specialty chemical project in collaboration with a Japanese company.
Discussions ongoing for two potential toll manufacturing projects with US and European companies; details under secrecy agreements.
Manufacturing business CapEx remains largely unchanged at approximately ₹58 crores.
Expansion potential exists: current acrylamide liquid capacity is 32,000 tons, with room to expand by another 60,000 tons.
PAM Solid project is under R&D for about a year with construction pending post-completion; technology being developed in-house.
Expected CapEx and construction timelines not disclosed due to confidentiality.

Track Black Rose Industries Ltd — get its next earnings analysis in your feed

How does Black Rose Industries Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

ThisBlack Rose Industries Ltd

Rev 3Mar 1

See where Black Rose Industries Ltd sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Black Rose Industries Ltd rank in Chemicals & Petrochemicals?

Compare Black Rose Industries Ltd against every Chemicals & Petrochemicals company (Q4 FY23) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

What Black Rose Industries Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

Neogen Chemicals Ltd (Q2 FY27)
Consolidated: ₹295.96 crore (up from ₹208.66 crore in Q3 FY25) . Key results statement takeaways from Neogen Chemicals Ltd's Q2 FY27 results statement — and how
Mahickra Chemicals Ltd (Q2 FY27)
682 million, a 34% year-on-year increase. Key results statement takeaways from Mahickra Chemicals Ltd's Q2 FY27 results statement — and how it ranks against sec
Vishnu Chemicals Ltd (Q2 FY27)
2,837.7 lakhs increase (~7.07% growth YoY). Key results statement takeaways from Vishnu Chemicals Ltd's Q2 FY27 results statement — and how it ranks against sec
Yasons Chemex (Q2 FY27)
4,927.35 lakhs for the same period in 2025, indicating a year-on-year decline of about 16.3% (Page 12). Key results statement takeaways from Yasons Chemex Care

Compare:vs Solar Industries vs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →